269 related articles for article (PubMed ID: 28424411)
41. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
[TBL] [Abstract][Full Text] [Related]
42. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
43. Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
Cheng W; Ainiwaer A; Xiao L; Cao Q; Wu G; Yang Y; Mao R; Bao Y
Mol Med Rep; 2015 Aug; 12(2):2451-6. PubMed ID: 25955495
[TBL] [Abstract][Full Text] [Related]
44. Swelling-induced chloride current in glioblastoma proliferation, migration, and invasion.
Wong R; Chen W; Zhong X; Rutka JT; Feng ZP; Sun HS
J Cell Physiol; 2018 Jan; 233(1):363-370. PubMed ID: 28262948
[TBL] [Abstract][Full Text] [Related]
45. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
[TBL] [Abstract][Full Text] [Related]
46. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
47. Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling.
Atif F; Yousuf S; Stein DG
J Steroid Biochem Mol Biol; 2015 Feb; 146():62-73. PubMed ID: 24787660
[TBL] [Abstract][Full Text] [Related]
48. Activation of sonic hedgehog signaling enhances cell migration and invasion by induction of matrix metalloproteinase-2 and -9 via the phosphoinositide-3 kinase/AKT signaling pathway in glioblastoma.
Chang L; Zhao D; Liu HB; Wang QS; Zhang P; Li CL; Du WZ; Wang HJ; Liu X; Zhang ZR; Jiang CL
Mol Med Rep; 2015 Nov; 12(5):6702-10. PubMed ID: 26299938
[TBL] [Abstract][Full Text] [Related]
49. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
Moser C; Lang SA; Hackl C; Wagner C; Scheiffert E; Schlitt HJ; Geissler EK; Stoeltzing O
Anticancer Res; 2012 Jul; 32(7):2551-61. PubMed ID: 22753713
[TBL] [Abstract][Full Text] [Related]
50. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
51. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
[TBL] [Abstract][Full Text] [Related]
52. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
[TBL] [Abstract][Full Text] [Related]
53. ILK silencing inhibits migration and invasion of more invasive glioblastoma cells by downregulating ROCK1 and Fascin-1.
Louca M; Zaravinos A; Stylianopoulos T; Gkretsi V
Mol Cell Biochem; 2020 Aug; 471(1-2):143-153. PubMed ID: 32506247
[TBL] [Abstract][Full Text] [Related]
54. Silencing of Eps8 blocks migration and invasion in human glioblastoma cell lines.
Cattaneo MG; Cappellini E; Vicentini LM
Exp Cell Res; 2012 Sep; 318(15):1901-12. PubMed ID: 22683923
[TBL] [Abstract][Full Text] [Related]
55. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.
Hong Z; Xiao M; Yang Y; Han Z; Cao Y; Li C; Wu Y; Gong Q; Zhou X; Xu D; Meng L; Ma D; Zhou J
Carcinogenesis; 2011 Oct; 32(10):1550-8. PubMed ID: 21803735
[TBL] [Abstract][Full Text] [Related]
56. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
Li Z; Graf N; Herrmann K; Jünger A; Aichler M; Feuchtinger A; Baumgart A; Walch A; Peschel C; Schwaiger M; Buck A; Keller U; Dechow T
Cancer Res; 2012 Oct; 72(19):5014-24. PubMed ID: 22875026
[TBL] [Abstract][Full Text] [Related]
57. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.
Weber GL; Parat MO; Binder ZA; Gallia GL; Riggins GJ
Oncotarget; 2011 Nov; 2(11):833-49. PubMed ID: 22064833
[TBL] [Abstract][Full Text] [Related]
58. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines.
Jung TY; Jung S; Ryu HH; Jeong YI; Jin YH; Jin SG; Kim IY; Kang SS; Kim HS
J Neurosurg; 2008 Aug; 109(2):273-84. PubMed ID: 18671640
[TBL] [Abstract][Full Text] [Related]
59. Activation of TRPM7 by naltriben enhances migration and invasion of glioblastoma cells.
Wong R; Turlova E; Feng ZP; Rutka JT; Sun HS
Oncotarget; 2017 Feb; 8(7):11239-11248. PubMed ID: 28061441
[TBL] [Abstract][Full Text] [Related]
60. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Kuger S; Flentje M; Djuzenova CS
Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]